Voluntary nationwide recall: Brexafemme
Oct. 2023Pharmacy Updates
Scynexis, Inc. is recalling two lots of Brexafemme (ibrexafungerp tablets) due to potential cross-contamination with a nonantibacterial ß-lactam drug substance in the ibrexafungerp citrate used to manufacture the Brexafemme tablets. This drug is used as an antifungal for the treatment of vulvovaginal candidiasis (VVC) and the reduction of the incidence of recurrent vulvovaginal candidiasis (RVVC). Read the full text of the voluntary Brexafemme recall.
Recent Announcements
Voluntary nationwide recall: Cetirizine (Unique – July)
Unique Pharmaceutical Laboratories (A Div. of J. B. Chemicals & Pharmaceuticals Ltd.) is recalling four lots (GY825029, GY825030, GY825031, GY825032) of Cetirizine Hydrochloride Tablets USP 5 mg. Cetirizine is used for the relief of allergy symptoms, including itchy, red, watery eyes and itchy skin.Jul. 2026Pharmacy Updates
August 2026 UPMC for You and UPMC Community HealthChoices Formulary Updates
Effective Aug. 15, 2026, UPMC for You and UPMC Community HealthChoices are updating their formularies.Jul. 2026Pharmacy Updates
Give feedback on your experience with UPMC Health Plan
You may be invited to participate in a 2026 Press Ganey provider satisfaction survey, which will begin next month. This survey will be given to a random sampling of in-network primary care providers.Jul. 2026Important Notices